Chronic cystamine treatment inhibits small artery remodelling in rats

Journal of Vascular Research

Volumn 44, Issue 6, 2007, Pages 471-482

  Eftekhari, Ashkan ^a   Rahman, Awahan ^a   Schæbel, Louise Holm ^a   Chen, Hua ^a   Rasmussen, Claus Vitrup ^a   Aalkjær, Christian ^a   Buus, Carsten Leander ^a   Mulvany, Michael J ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Cystamine; Hypertension; Remodelling; Tissue transglutaminase

Indexed keywords

AMLODIPINE; CYSTAMINE; PHENYLEPHRINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; DRUG INFUSION; ESSENTIAL HYPERTENSION; LONG TERM CARE; MALE; MEAN ARTERIAL PRESSURE; MYOGRAPHY; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; TREATMENT DURATION; TREATMENT OUTCOME; WISTAR RAT;

AMLODIPINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COLLAGEN; CYSTAMINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GELS; GTP-BINDING PROTEINS; HEART RATE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFUSION PUMPS; MALE; MESENTERIC ARTERIES; MICROSCOPY, CONFOCAL; PHENYLEPHRINE; RATS; RATS, WISTAR; TRANSGLUTAMINASES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 35648985034     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106465     Document Type: Article

References (47)

1. Staessen JA, Wang J, Bianchi G, Birkenhager WH: Essential hypertension. Lancet 2003;361:1629-1641.
2. Conway J: Hemodynamic aspects of essential hypertension in humans. Physiol Rev 1984;64:617-660.
3. Mulvany MJ: Changes to the vascular system resulting from hypertension and their effects on response to therapy. Drugs 1990;39(suppl 1):9-20.
4. Mulvany MJ, Aalkjaer C: Structure and function of small arteries. Physiol Rev 1990;70:921-961.
5. Mulvany MJ: Abnormalities of the resistance vasculature in hypertension: correction by vasodilator therapy. Pharmacol Rep 2005;57(suppl):144-150.
6. Korsgaard N, Aalkjaer C, Heagerty AM, Izzard AS, Mulvany MJ: Histology of subcutaneous small arteries from patients with essential hypertension. Hypertension 1993;22:523-526.
7. Mulvany MJ: Remodeling of resistance vessel structure in essential hypertension. Curr Opin Nephrol Hypertens 1993;2:77-81.
8. Mulvany MJ: Vascular remodelling of resistance vessels: can we define this? Cardiovasc Res 1999;41:9-13.
9. Mathiassen ON, Buus NH, Sihm I, Thybo NK, Morn B, Schroeder AP, Thygesen K, Aalkjaer C, Lederballe O, Mulvany MJ, Christensen KL: Small artery structure is an independent predictor of cardiovascular events in essential hypertension. J Hypertens 2007;25:1021-1026.
10. Christensen KL, Mulvany MJ: Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension: a literature survey. J Hypertens 2001;19:1001-1006.
11. Bakker EN, Der Meulen ET, Spaan JA, Van-Bavel E: Organoid culture of cannulated rat resistance arteries: effect of serum factors on vasoactivity and remodeling. Am J Physiol Heart Circ Physiol 2000;278:H1233-H1240.
12. Bakker EN, van der Meulen ET, van den Berg BM, Everts V, Spaan JA, VanBavel E: Inward remodeling follows chronic vasoconstriction in isolated resistance arteries. J Vasc Res 2002;39:12-20.
13. Bakker EN, Buus CL, VanBavel E, Mulvany MJ: Activation of resistance arteries with endothelin-1: from vasoconstriction to functional adaptation and remodeling. J Vasc Res 2004;41:174-182.
14. Bakker EN, Buus CL, Spaan JA, Perree J, Ganga A, Rolf TM, Sorop O, Bramsen LH, Mulvany MJ, VanBavel E: Small artery remodeling depends on tissue-type transglutaminase. Circ Res 2005;96:119-126.
15. Bakker EN, Pistea A, Spaan JA, Rolf T, de Vries CJ, van Rooijen N, Candi E, VanBavel E: Flow-dependent remodeling of small arteries in mice deficient for tissue-type transglutaminase: possible compensation by macrophage-derived factor XIII. Circ Res 2006;99:86-92.
16. Lorand L, Graham RM: Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003;4:140-156.
17. Bailey CD, Tucholski J, Johnson GV: Transglutaminases in neurodegenerative disorders. Prog Exp Tumor Res 2005;38:139-157.
18. Johnson TS, El Koraie AF, Skill NJ, Baddour NM, El Nahas AM, Njloma M, Adam AG, Griffin M: Tissue transglutaminase and the progression of human renal scarring. J Am Soc Nephrol 2003;14:2052-2062.
19. Maki M, Mustalahti K, Kokkonen J, Kulmala P, Haapalahti M, Karttunen T, Ilonen J, Laurila K, Dahlbom I, Hansson T, Hopfl P, Knip M: Prevalence of celiac disease among children in Finland. N Engl J Med 2003;348:2517-2524.
20. Borrell-Pages M, Canals JM, Cordelieres FP, Parker JA, Pineda JR, Grange G, Bryson EA, Guillermier M, Hirsch E, Hantraye P, Cheetham ME, Neri C, Alberch J, Brouillet E, Saudou F, Humbert S: Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 2006;116:1410-1424.
21. Griffin M, Casadio R, Bergamini CM: Transglutaminases: nature's biological glues. Biochem J 2002;368:377-396.
22. Jeitner TM, Delikatny EJ, Ahlqvist J, Capper H, Cooper AJ: Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochem Pharmacol 2005;69:961-970.
23. Bailey CD, Johnson GV: The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. Neurobiol Aging 2006;27:871-879.
24. Lesort M, Lee M, Tucholski J, Johnson GV: Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 2003;278:3825-3830.
25. Vecchione C, Fratta L, Rizzoni D, Notte A, Poulet R, Porteri E, Frati G, Guelfi D, Trimarco V, Mulvany MJ, Agabiti-Rosei E, Trimarco B, Cotecchia S, Lembo G: Cardiovascular influences of alpha1b-adrenergic receptor defect in mice. Circulation 2002;105:1700-1707.
26. Ibrahim J, Berk BC, Hughes AD: Comparison of simultaneous measurements of blood pressure by tail-cuff and carotid arterial methods in conscious spontaneously hypertensive and Wistar-Kyoto rats. Clin Exp Hypertens 2006;28:57-72.
27. McCarron JG, Quayle JM, Halpern W, Nelson MT: Cromakalim and pinacidil dilate small mesenteric arteries but not small cerebral arteries. Am J Physiol 1991;261:H287-H291.
28. El Nahas AM, Abo-Zenah H, Skill NJ, Bex S, Wild G, Griffin M, Johnson TS: Elevated epsilon-(gamma-glutamyl)lysine in human diabetic nephropathy results from increased expression and cellular release of tissue transglutaminase. Nephron Clin Pract 2004;97:c108-c117.
29. Laflamme MA, Myerson D, Saffitz JE, Murry CE: Evidence for cardiomyocyte repopulation by extracardiac progenitors in transplanted human hearts. Circ Res 2002;90:634-640.
30. Mulvany MJ, Halpern W: Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977;41:19-26.
31. Summey BT Jr, Graff RD, Lai TS, Greenberg CS, Lee GM: Tissue transglutaminase localization and activity regulation in the extracellular matrix of articular cartilage. J Orthop Res 2002;20:76-82.
32. Stankevicius E, Lopez-Valverde V, Rivera L, Hughes AD, Mulvany MJ, Simonsen U: Combination of Ca(2+)-activated K(+) channel blockers inhibits acetylcholine-evoked nitric oxide release in rat superior mesenteric artery. Br J Pharmacol 2006;149:560-572.
33. Folk JE, Cole PW: Mechanism of action of guinea pig liver transglutaminase. I. Purification and properties of the enzyme: identification of a functional cysteine essential for activity. J Biol Chem 1966;241:5518-5525.
34. Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany MJ: Small artery structure in hypertension. Dual processes of remodeling and growth. Hypertension 1993;21:391-397.
35. Bakker EN, Sorop O, Spaan JA, VanBavel E: Remodeling of resistance arteries in organoid culture is modulated by pressure and pressure pulsation and depends on vasomotion. Am J Physiol Heart Circ Physiol 2004;286:H2052-H2056.
36. Mancia G, Grassi G, Giannattasio C, Seravalle G: Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999;34:724-728.
37. Mhaouty-Kodja S: Ghalpha/tissue transglutaminase 2: an emerging G protein in signal transduction. Biol Cell 2004;96:363-367.
38. Fesus L, Piacentini M: Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 2002;27:534-539.
39. Parameswaran KN, Cheng XF, Chen EC, Velasco PT, Wilson JH, Lorand L: Hydrolysis of gamma:epsilon isopeptides by cytosolic transglutaminases and by coagulation factor XIIIa. J Biol Chem 1997;272:10311-10317.
40. Qiao SW, Piper J, Haraldsen G, Oynebraten I, Fleckenstein B, Molberg O, Khosla C, Sollid LM: Tissue transglutaminase-mediated formation and cleavage of histamine-gliadin complexes: biological effects and implications for celiac disease. J Immunol 2005;174:1657-1663.
41. Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJ, Ratan RR, Beal MF, Hersch SM, Ferrante RJ: Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 2002;22:8942-8950.
42. Dubinsky R, Gray C: CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. Mov Disord 2006;21:530-533.
43. Agah A, Kyriakides TR, Bornstein P: Proteolysis of cell-surface tissue transglutaminase by matrix metalloproteinase-2 contributes to the adhesive defect and matrix abnormalities in thrombospondin-2-null fibroblasts and mice. Am J Pathol 2005;167:81-88.
44. Lesort M, Lee M, Tucholski J, Johnson GV: Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 2003;278:3825-3830.
45. Johnson TS, Skill NJ, El Nahas AM, Oldroyd SD, Thomas GL, Douthwaite JA, Haylor JL, Griffin M: Transglutaminase transcription and antigen translocation in experimental renal scarring. J Am Soc Nephrol 1999;10:2146-2157.
46. Sorop O, Bakker EN, Pistea A, Spaan JA, VanBavel E: Calcium channel blockade prevents pressure-dependent inward remodeling in isolated subendocardial resistance vessels. Am J Physiol Heart Circ Physiol 2006;291:H1236-H1245.
47. Buus NH, Bottcher M, Jorgensen CG, Christensen KL, Thygesen K, Nielsen TT, Mulvany MJ: Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or beta-blockade in patients with essential hypertension. Hypertension 2004;44:465-470.